Tag: interleukin-1

August 18, 2021/COVID-19

Canakinumab for COVID-19 With Cardiac Injury: Early Trial Shapes Strategy for Future Investigation

Three C Study suggests 28-day efficacy window, 600-mg dose

November 17, 2020/Research

RHAPSODY Trial Reveals Unprecedented Reduction of Recurrent Pericarditis With Rilonacept

Phase 3 study may lead to first FDA approval for the indication

BackPage 1 of 1Next

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy